Figure 1Endogenous levels of sialic acids comprise self markers on normal cells，which may engageSiglec-7to aid in self recognition and suppress unwanted activation ofNKcells. （Left）Many cancer cells have higher levels of sialic acid (hypersialylated)，which could recruit moreSiglec-7and provide a strong inhibitory signal to theNKcells and help in immune evasion. （Right）
Biotinylated HumanSiglec-7，His，Avitag (Cat. No. SG7-H82E7) immobilized on CM5 Chip can bind Neu5Aca2-6GalNAca-PAA-biotin with an affinity constant of 29.2 nM as determined in a SPR assay (Biacore 8K) (QC tested).
1. Lunemann JD，von Gunten S，Neumann H. Targeting sialylation to treat central nervous system diseases. Trends Pharmacol Sci. 2021；42(12):998-1008.
2. Gianchecchi E，Arena A，Fierabracci A. Sialic Acid-Siglec Axis in Human Immune Regulation，Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments. Int J Mol Sci. 2021；22(11).
3. Avril T，North SJ，Haslam SM，Willison HJ，Crocker PR. Probing the cis interactions of the inhibitory receptorSiglec-7with alpha2，8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2，8-sialyltransferase gene expression. J Leukoc Biol. 2006；80(4):787-96.